17,261 trials
Dentinal Hypersensitivity
Primary: Mean Change From Baseline in Schiff Sensitivity Score at Week 4 — 2.39; 2.41; 2.40; 2.38 Score on a scale — p=0.4321
Recurrent Childhood Acute Lymphoblastic Leukemia
Primary: Remission Re-induction (CR2) Rate — .646; .660 proportion of participants
Ovarian Neoplasm · Fallopian Tube Cancer · Primary Peritoneal Cancer
Primary: Clinical Response Rate. — 0; 19; 21; 60 percentage of participants
Lymphoma
Primary: Event-free Survival After 12 Months — 78 percentage of participants
Lung Cancer
Primary: 8-Week Disease Control Rate (Complete Response, Partial Response and Stable Disease) — 33 percentage of participants
Leukemia
Primary: Complete Response Rate — 4 participants
Severe Sepsis
Primary: F2-isoprostanes After 72 Hours of Acetaminophen or Placebo — 33.4; 40.15 pg/mL — p=0.353
Kidney Transplant · Kidney Transplant Recipient · Graft Function/Survival
Primary: During Screening Phase: Incidence of Alloantibody Development — 79 participants
Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma · Stage I Mycosis Fungoides and Sezary Syndrome AJCC v7 · Stage II Mycosis Fungoides and Sezary Syndrome AJCC v7
Primary: Overall Response Rate — 6; 2; 8; 1 participants
Rheumatoid Arthritis
Primary: The Percentage of Subjects Achieving American College of Rheumatology (ACR) 20 Improvement — 66.7; 16.7; 66.7; 40.0 Percentage of participants
Male Breast Carcinoma · Stage IIA Breast Cancer AJCC v6 and v7 · Stage IIB Breast Cancer AJCC v6 and v7
Primary: Pathologic Complete Response (pCR) in the Breast. Defined as the Absence of Residual Invasive Carcinoma in the Breast (ypT0/is). — 60; 46 percentage of participants with…
Meningococcal Infections
Primary: Percentage of Subjects With Serum Bactericidal Activity ≥1:5 After Receiving Three Doses of rMenB+OMV NZ Vaccine — 9; 7; 6; 6 Percentages of subjects
Childhood Cerebellar Anaplastic Astrocytoma · Childhood Cerebral Anaplastic Astrocytoma · Childhood Cerebral Astrocytoma
Primary: Sustained Objective Response Rate — 0; 0 percentage of patients
Acne Scars
Primary: Global Scarring Severity — 2.7 units on a scale
Recurrent Skin Cancer · Squamous Cell Carcinoma of the Skin · Stage 0 Chronic Lymphocytic Leukemia
Primary: Objective Response Rate (Complete Response and Partial Response) — 0; 0 percentage of patients